Turning new corner, Winn-Dixie builds store
COVINGTON, La. —Winn-Dixie Stores in early February celebrated the completion of its new store, the first ground-up store for the grocer since 2004.
“We are very proud to be able to offer this beautiful store to the neighbors and communities of Covington,” stated Winn-Dixie chairman, CEO and president Peter Lynch. “Not only does it provide a best-in-class shopping experience, but it brings 200 new jobs to the area, as well.”
The 55,000-sq.-ft. supermarket, located a little north of New Orleans, features a 24-ft. tall open entrance way highlighted by an outdoor farmer’s market. Inside are a host of “enhanced” features, including a wine department staffed with a wine steward, a peanut butter machine and a full pharmacy department and wellness center.
Winn-Dixie offers several health testing services and immunization opportunities for consumers throughout the year. As a recent enhancement to its pharmacy offering, Winn-Dixie rolled out its WD RxConnect program chainwide. WD RxConnect links all of Winn-Dixie’s more than 400 pharmacies through a centralized prescription record system and also allows patients to access their own records online. “That’s kind of unique in the food store industry,” John Fegan, Winn-Dixie VP pharmacy, told Drug Store News earlier this year. “Under the WD RxConnect program, a patient can walk in, look up their medication history online and see what they’re taking.”
Report: Lawmakers seek to revise patent system
NEW YORK Lawmakers in Washington have taken steps to reform the U.S. patent system, according to published reports.
Reuters reported Thursday that Senate Judiciary Committee chairman Sen. Patrick Leahy, D-Vt., and other members Congress had reached an agreement on patent reform, introducing a bill that would allow the patent office to set its own fees and allow judges decide the importance of an infringed patent as part of a product.
Drug companies, which depend on small numbers of patents, have opposed the effort, while large computer and hardware companies have supported it, Reuters reported.
KV’s Ethex to plead guilty to criminal charges
ST. LOUIS The generic drug marketing and distribution division of KV Pharmaceuticals will plead guilty to criminal charges and close shop under a deal between KV and the Department of Justice, KV announced Thursday.
The generic drug maker said Ethex will plead guilty to two felony counts and pay $27.6 million to resolve a criminal investigation of the company that began amid allegations that it failed to file field alerts to inform regulators of manufacturing problems with the drugs dextroamphetamine and propafenone in 2008. The payment includes a fine, $2.3 million in restitution to the federal government and an administrative forfeiture of $1.8 million.
“This settlement marks an important milestone in our efforts to restore normalized business operations at KV, regain full regulatory and legal compliance and set KV on a new path moving forward,” KV interim CEO David Van Vliet said in a statement. “Management and the board have been working diligently to address this issue, and we are looking forward to having this matter resolved.”
Ethex recalled a large number of generic drugs in late 2008 and early 2009 due to problems such as possibly oversized tablets and manufacturing deficiencies. In March 2009, the Food and Drug Administration filed an injunction against KV to prevent it from making or distributing adulterated and unapproved drugs and forced it to destroy all the drugs it had recalled, forbidding it from resuming manufacturing until the FDA was satisfied that it had been brought back into compliance with regulations. KV said the current settlement would allow it to continue manufacturing once it had regained compliance with the FDA’s current good manufacturing practices regulations, also known as cGMP.